Lunit Highlights AI-Powered Pathology Insights Across Cancer Types at ESMO 2026
Five studies to be presented, with key research examining AI-based biomarker assessment and tumor microenvironment analysis in breast, lung and pancreatic cancers SEOUL, South Korea, Oct. 20, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that five studies involving its AI-powered pathology platform, Lunit SCOPE, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid, Spain. Lunit to Present Five Studies at ESMO 2026 The studies highlight how…
Read the full report on Pr Newswire Apac
Story file
- Section
- Science
- Topics
- AI & gadgets, Health alerts
- First reported by
- Pr Newswire Apac
- Reporter
- cision pr newswire
- Published
- Tuesday, 20 October 2026, 6:30 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Pr Newswire Apac with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
